Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature

Overview

Journal J Glob Oncol

Specialty Oncology

Date 2018 Sep 23

PMID 30241197

Authors

Francisco Socola

Veronica Hawes

Rodolfo Henrich Lobo

Appalanaidu Sasapu

Affiliations

Soon will be listed here.

References

Nemoto T, Saito Y, Tokuhira M, Tomikawa A, Sagawa M, Haba Y . [Acute-onset eosinophilic leukemia associated with tumor lysis syndrome after imatinib and steroid pulse therapy]. Rinsho Ketsueki. 2010; 51(5):326-31. View

Baccarani M, Cilloni D, Rondoni M, Ottaviani E, Messa F, Merante S . The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica. 2007; 92(9):1173-9. DOI: 10.3324/haematol.11420. View

Jovanovic J, Score J, Waghorn K, Cilloni D, Gottardi E, Metzgeroth G . Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia. Blood. 2007; 109(11):4635-40. DOI: 10.1182/blood-2006-10-050054. View

Pardanani A, Ketterling R, Li C, Patnaik M, Wolanskyj A, Elliott M . FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature. Leuk Res. 2006; 30(8):965-70. DOI: 10.1016/j.leukres.2005.11.011. View

Gleich G, Leiferman K, Pardanani A, Tefferi A, Butterfield J . Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002; 359(9317):1577-8. DOI: 10.1016/S0140-6736(02)08505-7. View

Ault P, Cortes J, Koller C, Kaled E, Kantarjian H . Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate. Leuk Res. 2002; 26(9):881-4. DOI: 10.1016/s0145-2126(02)00046-2. View

Klion A . How I treat hypereosinophilic syndromes. Blood. 2015; 126(9):1069-77. PMC: 4551360. DOI: 10.1182/blood-2014-11-551614. View

Pardanani A, Brockman S, Paternoster S, Flynn H, Ketterling R, Lasho T . FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004; 104(10):3038-45. DOI: 10.1182/blood-2004-03-0787. View

Arber D, Orazi A, Hasserjian R, Thiele J, Borowitz M, Le Beau M . The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391-405. DOI: 10.1182/blood-2016-03-643544. View

10.

Schaller J, Burkland G . Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. MedGenMed. 2001; 3(5):9. View

11.

Gotlib J . World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management. Am J Hematol. 2014; 89(3):325-37. DOI: 10.1002/ajh.23664. View